The patient was enrolled in the Randomized Embedded Multifactorial Adaptive Platform (REMAP)-COVID, a substudy of the trial REMAP-Community-Acquired Pneumonia (CAP). In the multicenter, randomized study, Amgen's apremilast drug and Eisai's investigational eritoran toll-like receptor 4 (TLR4) antagonist will be evaluated as potential therapeutic agents for COVID-19.

The trial is being conducted at the University of Pittsburgh Medical Center health system, along with over 20 other U.S. hospitals. Global sites will also be added to the trial, according to GCAR, Amgen, and Eisai.

Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies
Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.

Provention Bio, Amgen begin mAb trial for celiac disease
Provention Bio has begun a phase IIB study of PRV-015, an anti-interleukin-15 monoclonal antibody (mAb), in adult patients with nonresponsive celiac disease....

Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...

R&D Alliance begin I-Spy COVID trial
A collaborative research effort that includes the U.S. government and leading pharmaceutical companies has launched a clinical trial to investigate a...